222. Primary nephrotic syndrome
234 clinical trials,   241 drugs   (DrugBank: 78 drugs),   59 drug target genes,   185 drug target pathways
Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00977977 (ClinicalTrials.gov) | December 2, 2010 | 15/9/2009 | Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy | Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy | Nephrotic Syndrome;Proteinuria;Autoimmune Disease;Glomerular Disease;Membranous Glomerulonephritis | Drug: Rituximab Infusion;Drug: Oral Cyclosporine | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NULL | Recruiting | 18 Years | 100 Years | All | 30 | Phase 2 | United States |